In a mouse model of islet cell carcinoma, anti-VEGFR2 treatment was dichotomized into early- versus late-stage response.167 Initial regions of hypoxia induced by VEGFR2 blockade were circumvented by tumor cell expression of other angiogenic factors such as FGF. Here, KDR is linked to pancreatic endocrine carcinoma.